AnaptysBio, Inc. Common Stock (ANAB) — Analysis Summary
AnaptysBio, Inc. Common Stock (ANAB) has a market cap of $1.70B with year-over-year revenue growth of +157.0%. Net margin stands at -5.6%. The stock trades at a P/E ratio of -63.3.
Key Takeaways
- Revenue changed +157.0% year-over-year
- Net margin of -5.6%
- P/E ratio of -63.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ANAB posted revenue growth of +157.0% and trades at a P/E of -63.3.
AnaptysBio, Inc. Common Stock (ANAB)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin (17.6%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Net income fell 102.4% vs the prior period.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Sector
PHARMACEUTICAL PREPARATIONS
Employees
104
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.